RTP Mobile Logo
Beyond the Guidelines — Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Webinar Video Proceedings)
Released September 2021

Featuring perspectives from Drs Alexey V Danilov, Susan O’Brien, Sonali M Smith and Julie M Vose, moderated by Matthew S Davids. Published September 28, 2021. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

    LEARNING OBJECTIVES

    • Individualize the selection of systemic therapy for newly diagnosed chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
    • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to evaluate and select available options.
    • Appraise available and recently presented Phase III data documenting the comparative efficacy and tolerability of first- and second-generation BTK inhibitors, and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL.
    • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and appropriately integrate this regimen into current treatment decision-making.
    • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented Phase III data documenting the safety and efficacy of this strategy for patients with newly diagnosed CLL.
    • Analyze how patient age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for relapsed/refractory CLL.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for CLL.
    • Recall available and emerging data with other novel agents, combinations and strategies currently under investigation for CLL, and appropriately refer eligible patients for trial participation.

    CE ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
    In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIANS: The University of Nebraska Medical Center designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSES: The University of Nebraska Medical Center designates this activity for 2 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

    FOR SUCCESSFUL COMPLETION
    This CE activity consists of a video component. To receive credit, the participant should review the CE information, watch the video, complete the Post-test with a score of 100% (CME) or 80% (NCPD) and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/UNMCPanPacificCLL21/Video/CME or ResearchToPractice.com/UNMCPanPacificCLL21/Video/NCPD.

    CONTENT VALIDATION AND DISCLOSURES
    As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

    All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

    This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

    All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

    FACULTY — The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  

    Alexey V Danilov, MD, PhD
    Professor, Department of Hematology and Transplantation
    Co-Director, Toni Stephenson Lymphoma Center
    City of Hope National Medical Center
    Duarte, California

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, MEI Pharma Inc, Secura Bio, Takeda Oncology, TG Therapeutics Inc, Verastem Inc.

    Susan O’Brien, MD
    Associate Director for Clinical Science
    Medical Director, Sue and Ralph Stern Center for Clinical Trials and Research
    Chao Family Endowed Chair for Cancer Clinical Science
    Professor, Division of Hematology/Oncology, School of Medicine
    UCI Chao Family Comprehensive Cancer Center
    Orange, California

    Consulting Agreements: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, Aptose Biosciences Inc, Astellas, Autolus, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Juno Therapeutics, a Celgene Company, Lilly, Merck, NOVA Research Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc, Vaniam Group, Verastem Inc, Vida Ventures; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Caribou Biosciences Inc, Gilead Sciences Inc, Kite, A Gilead Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc.

    Sonali M Smith, MD
    Elwood V Jensen Professor of Medicine
    Chief, Section of Hematology/Oncology
    Co-Leader, Cancer Service Line
    Co-Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc.

    Julie M Vose, MD, MBA
    Neumann M and Mildred E Harris Professor
    Chief, Hematology/Oncology
    University of Nebraska Medical Center
    Omaha, Nebraska

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Conjuro, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, MorphoSys, Oncternal Therapeutics, Roche Laboratories Inc, Umoja Biopharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Seagen Inc; Data and Safety Monitoring Board/Committee: MEI Pharma Inc.

    Moderator
    Matthew S Davids, MD, MMSc
    Associate Professor of Medicine
    Harvard Medical School
    Director of Clinical Research
    Division of Lymphoma
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc.

    UNMC AND RESEARCH TO PRACTICE CE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS —The below planning committee members have nothing to disclose:
    Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC— RTP Reviewer, and Kathryn Ault Ziel, PhD—RTP Staff and Planner.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and UNMC do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and TG Therapeutics Inc.

    Release date: September 28, 2021
    Expiration date: September 28, 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):